Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses of $(0.53) per share from the same period last year. The company reported $986.000 thousand in sales this quarter. This is a 63.79 percent decrease over sales of $2.723 million the same period last year.
Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.